LEONARDI, FRANCESCO
 Distribuzione geografica
Continente #
EU - Europa 147
NA - Nord America 147
AS - Asia 21
Totale 315
Nazione #
US - Stati Uniti d'America 147
IE - Irlanda 52
IT - Italia 32
SE - Svezia 24
AT - Austria 20
CN - Cina 13
FI - Finlandia 6
GB - Regno Unito 5
BE - Belgio 3
SG - Singapore 3
DE - Germania 2
IR - Iran 2
MK - Macedonia 2
PK - Pakistan 2
CZ - Repubblica Ceca 1
KZ - Kazakistan 1
Totale 315
Città #
Dublin 52
Chandler 45
Ashburn 24
Vienna 16
Parma 14
Boardman 9
Shanghai 9
Ann Arbor 7
Helsinki 6
Princeton 5
Graz 4
New York 4
Brussels 3
London 3
Beijing 2
Borås 2
Bremen 2
Houston 2
Karak 2
Liberty Lake 2
Milton Keynes 2
Neviano degli Arduini 2
Rosate 2
Skopje 2
Almaty 1
Ardabil 1
Brno 1
Des Moines 1
Fremont 1
Miami 1
Milan 1
Ozzano dell'Emilia 1
Taiyuan 1
Washington 1
Wilmington 1
Zanjan 1
Totale 233
Nome #
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 83
Stage III and metastatic Lymph Node Ratio are the only independent prognostic factors in colorectal signet-ring cell carcinoma patients 70
Should patients on levothyroxine therapy be screened for pancreatic cancer? 41
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 32
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 27
Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study 25
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) 25
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 23
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 8
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 2
Totale 336
Categoria #
all - tutte 1.559
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.559


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202135 0 0 0 11 0 11 7 2 0 0 2 2
2021/202223 0 1 2 0 1 0 7 1 1 0 1 9
2022/2023205 10 28 9 15 10 19 6 18 66 4 11 9
2023/202473 8 7 6 3 7 19 9 7 1 6 0 0
Totale 336